Biosergen AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	15.37	50.61	1.88	29.34	21.67
Cash & Short-Term Investments	15.37	50.61	1.88	29.34	21.67
Cash Growth	-69.64%	2587.84%	-93.58%	35.44%	-
Other Receivables	6.21	1.95	4.93	4.02	7.47
Receivables	6.21	1.95	4.93	4.02	7.47
Prepaid Expenses	-	0.46	0.39	0.43	0.35
Total Current Assets	21.58	53.02	7.2	33.79	29.49
Total Assets	21.58	53.02	7.2	33.79	29.49
Accounts Payable	-	2.38	1.7	6.81	6.75
Accrued Expenses	-	2.4	3.26	4	2.41
Other Current Liabilities	11.09	0.03	0.13	0.18	0.1
Total Current Liabilities	11.09	4.81	5.09	11	9.25
Other Long-Term Liabilities	2.37	-	-	-	-0
Total Liabilities	13.46	4.81	5.09	11	9.25
Common Stock	8.12	5.87	1.27	1.06	0.7
Comprehensive Income & Other	-	42.34	0.85	21.73	19.53
Shareholders' Equity	8.12	48.21	2.12	22.79	20.23
Total Liabilities & Equity	21.58	53.02	7.2	33.79	29.49
Net Cash (Debt)	15.37	50.61	1.88	29.34	21.67
Net Cash Growth	-69.64%	2587.84%	-93.58%	35.44%	-
Net Cash Per Share	6.54	21.09	3.69	93.93	77.02
Filing Date Shares Outstanding	2.35	2.35	0.51	0.42	0.28
Total Common Shares Outstanding	2.35	2.35	0.51	0.42	0.28
Working Capital	10.48	48.21	2.12	22.79	20.23
Book Value Per Share	3.46	20.53	4.17	53.72	72.00
Tangible Book Value	8.12	48.21	2.12	22.79	20.23
Tangible Book Value Per Share	3.46	20.53	4.17	53.72	72.00

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.